| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.05 | 0.4 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | AZD7762 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.044 | 0.4 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | 0.25 | 0.4 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | Fumonisin B1 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.4 |